129 related articles for article (PubMed ID: 36239065)
21. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer.
Berg S; Cole AP; Krimphove MJ; Nabi J; Marchese M; Lipsitz SR; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Eur Urol; 2019 Apr; 75(4):552-555. PubMed ID: 30420255
[TBL] [Abstract][Full Text] [Related]
23. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of treatments for high-risk prostate cancer patients.
Jayadevappa R; Lee DI; Chhatre S; Guzzo TJ; Malkowicz SB
Urol Oncol; 2019 Sep; 37(9):574.e11-574.e18. PubMed ID: 31285113
[TBL] [Abstract][Full Text] [Related]
25. The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
Song P; Shu M; Yang L; Di X; Liu P; Liu Z; Zhou J; Dong Q
Urol Int; 2022; 106(1):11-19. PubMed ID: 34515256
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Brachytherapy; 2015; 14(1):29-36. PubMed ID: 25443528
[TBL] [Abstract][Full Text] [Related]
27. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
29. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
30. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Sorensen SV; Peng S; Monz BU; Bradley-Kennedy C; Kansal AR
Pharmacoeconomics; 2013 Jul; 31(7):589-604. PubMed ID: 23615895
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer.
Wolff RF; Ryder S; Bossi A; Briganti A; Crook J; Henry A; Karnes J; Potters L; de Reijke T; Stone N; Burckhardt M; Duffy S; Worthy G; Kleijnen J
Eur J Cancer; 2015 Nov; 51(16):2345-67. PubMed ID: 26254809
[TBL] [Abstract][Full Text] [Related]
32. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer.
Naser-Tavakolian A; Venkataramana A; Spiegel B; Almario C; Kokorowski P; Freedland SJ; Anger JT; Leppert JT; Daskivich TJ
Urol Oncol; 2023 Apr; 41(4):205.e1-205.e10. PubMed ID: 36737259
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
34. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
Lardas M; Liew M; van den Bergh RC; De Santis M; Bellmunt J; Van den Broeck T; Cornford P; Cumberbatch MG; Fossati N; Gross T; Henry AM; Bolla M; Briers E; Joniau S; Lam TB; Mason MD; Mottet N; van der Poel HG; Rouvière O; Schoots IG; Wiegel T; Willemse PM; Yuan CY; Bourke L
Eur Urol; 2017 Dec; 72(6):869-885. PubMed ID: 28757301
[TBL] [Abstract][Full Text] [Related]
35. Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
Sebastian NT; McElroy JP; Martin DD; Sundi D; Diaz DA
Urol Oncol; 2019 Nov; 37(11):813.e11-813.e19. PubMed ID: 31109836
[TBL] [Abstract][Full Text] [Related]
36. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported functional outcome measures and treatment choice for prostate cancer.
Tiruye T; O'Callaghan M; Moretti K; Jay A; Higgs B; Santoro K; Boyle T; Ettridge K; Beckmann K
BMC Urol; 2022 Nov; 22(1):169. PubMed ID: 36335325
[TBL] [Abstract][Full Text] [Related]
40. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Grimm P; Billiet I; Bostwick D; Dicker AP; Frank S; Immerzeel J; Keyes M; Kupelian P; Lee WR; Machtens S; Mayadev J; Moran BJ; Merrick G; Millar J; Roach M; Stock R; Shinohara K; Scholz M; Weber E; Zietman A; Zelefsky M; Wong J; Wentworth S; Vera R; Langley S
BJU Int; 2012 Feb; 109 Suppl 1():22-9. PubMed ID: 22239226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]